Noninvasive assessment of glymphatic dysfunction in idiopathic normal pressure hydrocephalus with diffusion tensor imaging.
Charalampos Georgiopoulos, Anders Tisell, Rafael T Holmgren...
https://pubmed.ncbi.nlm.nih.gov/37724800/Actively Recruiting
Led by Xuanwu Hospital, Beijing · Updated on 2024-05-24
200
Participants Needed
1
Research Sites
50 weeks
Total Duration
Researchers are studying idiopathic normal pressure hydrocephalus iNPH and related disorders to understand their clinical characteristics and natural progression. This prospective single-center study aims to identify digital, imaging, and molecular biomarkers that can help with diagnosis and therapy development. It also explores the causes and molecular mechanisms of these conditions to better understand their effects and outcomes. Participants are divided into groups including those diagnosed with hydrocephalus and a normal group. The study involves advanced diagnostic tests such as high throughput sequencing, whole genome and exome sequencing, transcriptomics, proteomics, metabolomics, and imaging techniques like DTIALPS. These tests are conducted to gather comprehensive data on the disease and its biomarkers. During study visits, patients undergo standardized clinical examinations and complete clinical rating scales. Biosamples such as blood, urine, cerebrospinal fluid, and muscle biopsies may be collected optionally. Additional assessments like neurophysiological exams, patient-reported outcomes, and imaging are also performed. Researchers measure changes from baseline in DTIALPS imaging and various clinical scales six months after ventriculoperitoneal shunt surgery. The study includes monitoring cognitive function, gait, and molecular patterns, with participation lasting through these assessments and follow-ups.
CONDITIONS
Clinical Outcome in Patients With INPH
F
fengzeng jian, md
X
xin qu, md
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Xuanwu Hospital, Beijing
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 months
Participants undergo diagnostic tests including high throughput sequencing, electromyography, whole genome sequencing, transcriptomics, proteomics, metabolomics, and imaging such as DTIALPS to assess their condition.
Multiple visits during the 6 months before surgery
Duration - 6 months after surgery
Participants are monitored over time with clinical rating scales and optional biosample collections including blood, urine, cerebrospinal fluid, and muscle biopsy. Additional optional examinations such as neurophysiological tests and imaging may occur to track disease progression and outcomes.
Regular visits during the 6 months after surgery
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Charalampos Georgiopoulos, Anders Tisell, Rafael T Holmgren...
https://pubmed.ncbi.nlm.nih.gov/37724800/Chenghua Yuan, Pingchuan Xia, Wanru Duan...
https://pubmed.ncbi.nlm.nih.gov/38014747/Chao Zhang, Kai Xu, Haiyan Zhang...
https://pubmed.ncbi.nlm.nih.gov/37010581/Xuanwu Hospital, Beijing
Lead Sponsor